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Cristina Fondi,1 Chiara Nozzoli,2 Silvia Benemei,3 Gianna Baroni,1 Riccardo Saccardi,2
Stefano Guidi,2 Paola Nicoletti,3 Benedetta Bartolozzi,2 Nicola Pimpinelli,4 Marco Santucci,1
Alberto Bosi,2 Daniela Massi11 1In animal models, CD4 /CD25 T-regulatory cells (Tregs) have been reported to prevent/delay the onset of
graft-versus-host disease (GVHD). Recently, an insufficient upregulation of Tregs was found in target organ
(intestinal) biopsies from patients with GVHD. We have analyzed by immunohistochemistry the number of
CD31 T lymphocytes and FOXP31 Tregs in skin biopsies from (1) recipients of allogeneic hematopoietic
stem cell transplantation (HSCT, n5 26), (2) nontransplanted patients diagnosed with cutaneous drug reac-
tion (n5 12), and (3) healthy donors (n5 10). Infiltrating CD31 cells were significantly higher in both trans-
planted patients showing acute GVHD (aGVHD) and drug reaction when compared to healthy donors and
patients without GVHD. Tregs number in aGVHDwas higher than in patients without GVHD or healthy sub-
jects and lower than in drug reaction. Interestingly, the number of infiltrating FOXP31 Tregs was significantly
higher in patients responding to GVHD treatment and with a low GVHD grade. Increase in FOXP31 Tregs in
GVHD skin biopsies correlates with less severe GVHD and is associated with response to GVHD treatment.
Larger studies are required to confirm that evaluation of Tregs in minimally invasive skin biopsies assists the
diagnosis and prognosis of GVHD patients.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is successfully applied to the treatment of
hematopoietic malignancies as well as genetic disor-
ders. However, the application of allo-HSTC is lim-
ited because of severe life-threatening complications
such as graft-versus-host disease (GVHD) [1,2].
Reduction in conditioning regimen-related toxicity,
which results in a wider application of allo-HSCT,
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6/j.bbmt.2009.04.009[3,4]. Depending on the different type of transplanta-
tion, immunosuppressive treatment and underlying
diseases, between 35% and 70% of patients develop
GVHD after allo-HSCT, with.35% of these patients
requiring specific immunosuppressive therapy [5].
In the development of GVHD, donor T lympho-
cytes responding to the allogeneic antigens undergo
clonal expansion, developing cytotoxic reactivity
against recipient histocompatibility antigens. Re-
cently, much attention has been directed to regulatory
T (Treg) cells and to their potential to attenuate
GVHD in animal models [6,7]. In particular, CD41/
CD251 Tregs cells have been proposed to play a key
role because they inhibit activation of reactive T cells
in an antigen-specific and cell contact-dependent man-
ner [8-11]. This effect may delay the onset or prevent
the occurrence of GVHD [12-14].
In humans, the impact of Treg cell count in the
prognosis of GVHD is controversial, and discrep-
ancies may result from differences in surface pheno-
typing techniques used to characterize these cells
[15-22]. In most studies Treg phenotype has been ob-
tained by CD4 and CD25 coexpression. However, in
humans, CD25 (interleukin-2 receptor a chain) is
also expressed by recently activated T cells. FOXP3,
which encodes a forkhead-winged-helix transcription
Table 1. Characteristics of Patients Undergoing Allogeneic
Stem Cell Transplantation (n5 26)
GVHD
(n5 20)
no GVHD
(n5 6)
Median age, years 47 45
Sex
Male 12 4
Female 8 2
Diagnosis
Chronic myeloproliferative syndrome 3 1
Acute lymphoblastic leukemia 2 1
Acute myelogenous leukemia 4 2
Chronic lymphocytic leukemia 1 0
Myelodysplastic syndrome 1 0
Multiple myeloma 4 2
Non-Hodgkin lymphoma 3 0
Hodgkin lymphoma 1 0
Aplastic anemia 1 0
Conditioning regimen
Myeloablative 6 4
Reduced-intensity 14 2
Stem cell source
Bone marrow 5 5
Peripheral blood 14 1
Cord blood 1 0
Donor
Related 11 5
Unrelated 9 1
GVHD reactions
Acute 14
Chronic 9
Acute GVHD grade
Grade I 4
Grade II-IV 10
Median time after transplantation (range),
days
22 (10-40)
Chronic GVHD grade
Limited 3
Extensive 6
Chronic GVHD
De novo 5
Progressive 4
Median time
after transplantation (range), days
188 (120-468)
Prophylaxis
CsA +MTX 13 5
Biol Blood Marrow Transplant 15:938-947, 2009 939Tregs in Skin GVHDfactor designated Scurfin [23], is currently considered
the more specific marker for Tregs [24,25]. An addi-
tional confounding factor derives from the fact that
evaluation of Tregs has been performed in peripheral
blood, a compartment that may not reflect their num-
ber in target organs of GVHD, such as the gut, the
liver, and the skin.
Recently, FOXP31 Tregs were found to be ex-
panded in intestinal biopsies of allografted patients
without GVHD and selectively downregulated in bi-
opsies of patients with GVHD, thus suggesting that
an insufficient upregulation of Tregs in the target or-
gan may contribute to the underlying mechanism of
the disease [26]. However, it is not known if Tregs
downregulation is a unique feature of intestinal
GVHD or if it can be found in other tissues and organs
affected by GVHD, including the liver and the skin. In
addition, skin rashes of GVHD show overlapping
features with various cutaneous erythematous drug
reactions, not infrequently observed in posttransplan-
tation period, thus raising a challenging diagnosis with
relevant therapeutic consequences [27].
In the present investigation, we have compared the
number of CD41/CD251/FOXP31 Tregs in skin
biopsies taken under different clinical circumstances,
including, (1) lesional skin of acute GVHD (aGVHD)
or chronic GVHD (cGVHD) patients, (2) in HSCT
recipients without GVHD showing mild to moderate
erythema (non-GVHD rash), (3) lesional skin from
nontransplanted patients with cutaneous drug reac-
tions, and (4) healthy skin from patients undergoing
plastic surgery. An increased number in Tregs was as-
sociated to a favorable outcome of both aGVHD and
cGVHD. Thus, present results support the hypothesis
that FOXP31 Tregs exert a protective role in cutane-
ous GVHD.CsA +MMF 7 1
T cell
depletion (ATG)
Yes 6 1
No 0 5
Response to GVHD therapy
Refractory* 7
Responsive 13
GVHD indicates graft-versus-host disease; ATG, antithymocyte globulin;
CSA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil;
*Patients refractory to therapy were defined as patients experiencing
progression after 3 days or no change after 7 days or incomplete
response after 14 days of specific GVHD therapy.PATIENTS, MATERIALS, AND METHODS
Patients and Samples
A retrospective analysis of 48 paraffin-embedded
tissue samples obtained from the Department of Hu-
man Pathology and Oncology, University of Florence,
was performed. Biopsies were taken from: (1) normal
healthy skin (n5 10) obtained from residual specimens
discarded after plastic surgery of the breast or abdomen;
(2) skin biopsies taken on cutaneous erythemas (n5 6)
from patients undergoing allogeneic stem cell trans-
plantation (SCT; biopsied from 14 to 71 days upon
transplantation, median 27 days), who subsequently
did not develop clinical GVHD (non-GVHD rash cat-
egory); (3) skin biopsies taken on erythematousmacular
and/or papular rash (n5 20) in allografted patients with
clinical signs of (suspect) GVHD, graded according to
standard criteria; and (4) skin biopsies from nonallog-
rafted patients with clinically and histopathologicallyconfirmed drug reactions (n5 12). Specifically, the
non-GVHD rash group included transplanted patients
experiencing erythematous rashes in the posttransplant
period. Biopsies were performed in these patients to
clarify the nature (toxic versus drug-induced versus viral
versusGVHD) of the skin rash. To be included into the
non-GVHDrashgroup, patients shouldnot have devel-
oped any clinical manifestation related to GVHD in-
volving either the skin or other organs and experienced
940 Biol Blood Marrow Transplant 15:938-947, 2009C. Fondi et al.rash resolution in absence of specific GVHD treat-
ments. Among 6 non-GVHD rash patients, 3 patients
experienced HHV6 or cytomegalovirus (CMV) reacti-
vation and the rash disappeared upon antiviral treat-
ment. Three additional patients were interpreted as
probable drug-induced rashes. For patients with clini-
cal grade .I GVHD, the diagnosis was made on the
basis of concomitant and/or subsequent involvement
of other organs (eg, gastrointestinal, liver) and/or
decrease of performance status. Patients with clinical
grade I GVHD had skin rashes involving 25% to
50% of body surface, and were not on drug therapy po-
tentially inducing cutaneous reaction (trimethoprim/
sulfamethoxylol or allopurinol). Diagnostic biopsies
in GVHD patients were taken before any specific
GVHD treatments were initiated. The study was re-
viewed and approved by the institutional review board
of the University of Florence.
Details of patients undergoing allogeneic bone
marrow transplantation are reported in Table 1. Ten
patients received a conventional myeloablative condi-
tioning regimen and 16 patients received reduced-in-
tensity conditioning (RIC) regimen. Specifically,
within the myeloablative (MA), 4 were total body irra-
diation containing cyclophosphamide (TBI/Cy) and 6
chemotherapy based on busulfan and Cy (Bu/Cy);
within the nonmyeloablative (NMA), 8 were TBI con-
taining fludarabine and [Fill in what "M" is] (TBI/
Flu6M) and 8 chemotherapy based (TTCY). All pa-
tients were treated with standard prophylaxis for
GVHD (cyclosporing [CsA] 1 methotrexate [MTX]
in 18 patients and CSA1MMF in 8 cases) and 7 cases
of transplantation from unrelated donor received addi-
tional T cell depletion with antithymocyte globulin
(ATG). Themajority (16 patients) received transplants
from matched related donors and 10 from unrelated
donors. Stem cell source was bone marrow (BM) in
10 cases, peripheral blood (PB) in 15 cases, and cord
blood (CB) in 1 case. HLA matching was 6/6 in all
identical sibling and unrelated donor (PB and BM)
transplants, the cord blood transplant (CBT) was per-
formed with 2 CB units at least 4/6 matched. Fourteen
patients experienced aGVHD (Grade I in 4 cases,
Grade .I in 10 cases) and 9 patients cGVHD (de
novo in 5 patients and progressive in 4 patients).
cGVHD was limited in 3 patients and extensive in 6Table 2. Phenotype of the Lymphocytic Infiltrate in 48 Skin Biops
Transplanted Patients and Control Drug Reactions
Cell Type
Healthy Skin
(n5 10) Non-GVHD rash (n5 6)
FOXP3+ 1.43 ± 0.22 0.23 ± 0.16
CD4+ 5.08 ± 0.25 4.37 ± 2.80
CD25+ 5.90 ± 0.43 4.20 ± 1.43
CD3+ 10.94 ± 1.12 11.20 ± 6.24
GVHD indicates graft-versus-host disease; cGVHD, chronic graft-versus-host
Mean number of CD3+, CD4+, CD25+, and FOXP3+ lymphocytes per HPF, capatients. GVHD first line treatment consisted in
methylprednisolone at the dose of 2 mg/kg in
GVHD and 1 mg/kg in cGVHD. Patients refractory
to therapy were defined as patients experiencing pro-
gression after 3 days or no change after 7 days or in-
complete response after 14 days of specific GVHD
therapy.Immunohistochemical Analysis
Immunohistochemical staining was performed on
3 mm-thick serial sections cut from formalin-fixed and
paraffin-embedded tissues. All tissue sections were
placed on Ventana automated stainer BenchMark
XT ICH system, deparaffined, reydrated, and pro-
cessed blocking endogenous peroxidase and epitope
retrieval. The following primary antibodies were
used: anti-CD3 (CD3 polyclonal antibody; Cell Mar-
que; CA, ready to use); anti-CD4 (CD4 monoclonal
antibody, [mAb] clone 1F6, Diapath, Italy; dilution
1:10); anti-CD25 (CD25 mAb clone 4C9, Novocas-
tra, UK, dilution 1:20). Primary antibodies were
placed on tissue sections and incubated for 32 min-
utes at 37C using as rivelation system iVIEW
DAB Detection Kit. After completion of the staining
run, sections were counterstained with hematoxylin.
Additional sections from the same specimens were
deparaffined in Bio-Clear (Bio-Optica, Milan, Italy)
hydrated with grade ethanol concentration until dis-
tilled water and placed in 3% hydrogen peroxide/
H2O2. for blocking endogenous peroxidase. Antigen
retrieval by microwave pretreatment in Citrate buffer
10 mM pH 6.0 for 30 minutes was followed by incu-
bation with the mAb anti-FOX-P3 (FOXP3 mAb,
Abcam, DBA, Milan, Italy; dilution 1:40). Bound an-
tibody was evaluated using streptavidin-biotin-perox-
idase complex technique and 3,30 diaminobenzidine
(liquid DAB, DAKO) as chromogen. The sections
were lightly counterstained with Mayer’s hematoxy-
lin. A negative control was included with each run
by omitting the primary antibody and yielded no sig-
nal. As positive control, a tonsil tissue specimen was
used. The control sections were treated in parallel
with the samples in the same run. Quantification of
the frequency of immunostained cells was performed
in the single-stained serial sections. The number ofies of Healthy Skin, Non-GVHD rash, aGVHD and cGVHD in
aGVHD (n5 13) cGVHD (n5 7)
Drug Reactions
(n5 12)
6.09 ± 1.57 4.66 ± 1.65 20.35 ± 4.39
16.12 ± 3.56 8.17 ± 3.64 47.54 ± 7.756
15.52 ± 3.02 9.06 ± 2.56 22.09 ± 1.60
86.46 ± 20.53 49.77 ± 13.29 91.90 ± 10.66
disease; aGVHD, acute graft-versus-host disease; HFP, high power field.
lculated in 5 HPF. Results are expressed as mean6 SEM.
Figure 1. Histology and immunohistochemistry for CD3, CD4, CD25, and FOXP31 T cells of representative skin biopsies from normal skin,
allografted patients with or without GVHD, and drug reactions. A small amount of CD31 T cells and a low number of regulatory T FOXP3 is observed
in the healthy skin, (A) whereas skin biopsies of patients with GVHD shows a high number of CD31 and an intermediate amount of FOXP31 T cells
mainly observed in the dermoepidermal junction and superficial dermis. In contrast, skin biopsies taken from drug reactions (B) show an elevated num-
ber of CD31 and FOXP31 cells at the dermoepidermal junctions and superficial dermis especially around keratinocytes displaying many characteristic
apoptotic bodies (original magnification 20). Stains: hematoxylin and eosin (H&E, top row); APAAP and immunoperoxide.
Biol Blood Marrow Transplant 15:938-947, 2009 941Tregs in Skin GVHDFOXP31 Tregs was quantified (mean number/high
power field (HPF) calculated in 5 HPF) and related
to the number of CD31 T lymphocytes (FOXP3/
CD3 ratio).To determine whether, in our present conditions,
FOXP31 antibody effectively identified a subset of
selective CD41/CD251 cells, a double-labeling of
FOXP32CD25 and FOXP32CD4 was performed in
Figure 1. (continued).
942 Biol Blood Marrow Transplant 15:938-947, 2009C. Fondi et al.a series of 12 different patients representing all
groups of cases investigated in the present study.
Anti-CD25 and anti-CD4 antibodies were used
with the above-described conditions. For anti-Fox-
P3 antibody streptavidin-biotin-phosphatase as reve-
lation system and nitro blue tetrazolium as chromo-
gen were employed. Double labeling invariablyconfirmed the expression of CD25 and CD4 in
FOXP31 cells.Statistical Analysis
Results are expressed as mean6 SEM. Statistical
analysis was performed by the 2-tailed Student’s t-test
Biol Blood Marrow Transplant 15:938-947, 2009 943Tregs in Skin GVHDor the analysis of variance followed by the Bonferroni’s
post hoc test. A value of p \ .05 was considered
significant.RESULTS
Histopathologic Examination of Skin Biopsies
Histopathologic examination of biopsies taken
from erythema in patients that did not develop
GVHD (non-GVHD rash category) showed focal or
diffuse vacuolar degeneration of the basal epidermal
cells (4 cases) and a perivascular and interstitial mixed
inflammatory infiltrate with scattered eosinophils and
mild spongiosis (urticarial-like changes) in 2 cases.
Biopsies from erythematous macular and/or papular
rashes in GVHD patients, taken before day 100 (13
cases) showed signs of aGVHD (Lerner et al [28]
grade 1: n5 2, grade 2: n5 2, grade 3: n5 9) and after
day 100 in 7 cases displayed evidence for possible
cGVHD in 4 cases and for consistent with cGVHD
in 3 cases, according to currently accepted criteria
[29]. Histopathologically, all drug reactions showed
an interface dermatitis characterized by diffuse vacuo-
lar degeneration of the basal epidermal cells, colloid
bodies, and a lichenoid and/or dermal perivascular
mixed inflammatory infiltrate, with scattered
eosinophils.Figure 2. FOXP3 brown nuclear staining shows a few FOXP31 Tregs cells (ast
magnification20). Double immunohistochemical staining shows that all FOXP
membranous staining, left panel, original magnification 40) and all FOXP31
membranous staining, right panel, original magnification 40).Increased T Cell Infiltration in the Skin of
Patients with aGVHD and with Drug Reactions
in Nonallografted Patients
By conventional immunohistochemical analysis,
we demonstrated that CD31 T cell number was mark-
edly and similarly elevated in aGVHD and drug reac-
tions compared to the small and similar number found
in both healthy skin and in erythematous skin in non-
GVHD rashes (Table 2). In cGVHD, the number of
CD31 cells was intermediate between those observed
in aGVHD and drug reaction, but without reaching
the statistically significant level (Table 2; Figure 3,
upper panel).The numbers of FOXP31 Tregs in aGVHD Is
Intermediate between Non-GVHD Rashes and
Cutaneous Drug Reactions
Despite similar T cell numbers, the pattern of the
skin-infiltrating T lymphocytes differed remarkably
between patients with GVHD and patients with drug
reactions (Figure 1). Double immunohistochemical
staining showed that all FOXP31 cells were CD31
and coexpressed CD4 and CD25 (Figure 2). In skin
specimens from non-GVHD rashes, we found a low
number of FOXP31 Tregs similar to that observed
in healthy skin. In aGVHD, FOXP31 cells were inter-
mediate between the low level observed in non-erisks) in aGVHD skin biopsy in comparison with drug reaction (original
31 cells coexpress CD4 (FOXP3 in blue nuclear staining, CD4 in brown
cells express CD25 (FOXP3 in blue nuclear staining, CD25 in brown
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Figure 3. Number of CD31 T cells (A), FOXP31 Tregs (B), or ratio of
FOXP31 per 100 CD31 cells in paraffin-embedded biopsies of healthy
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944 Biol Blood Marrow Transplant 15:938-947, 2009C. Fondi et al.GVHD rashes and the elevated number found in
cutaneous drug reactions (Table 2; Figure 3, mid
panel). In cGVHD the number of FOXP31 cells was
not statistically different from the values obtained in
other clinical conditions (Table 2; Figure 3, mid
panel). The FOXP31 Tregs/CD31 ratio (Figure 3,
lower panel) was similarly high in healthy skin and in
skin from drug reactions, indicating that in this latter
condition the 2 lymphocyte subsets show a parallel in-
crease in their respective absolute number. The statis-
tically higher ratio found in these 2 conditions
compared to skin biopsies from non-GVHD rashes,
indicated that, in this latter circumstance, there is a se-
lective deficient recruitment in the skin of the skin. In
both aGVHD and cGVHD the FOXP31 Tregs/
CD31 ratio was intermediate, but not statistically
different from those observed in the other conditions.
Decreased Number of FOXP31 Tregs Is
Associated with the Severity of GVHD and
Treatment Response
In patients submitted to allo-HSCT, the number
of CD31 cells and FOXP31Tregs was similar in stan-
dard MA and RIC transplantation (Figure 4A and B).
In patients with aGVHD, the number of FOXP31
Tregs was significantly reduced in skin biopsies of pa-
tients classified as clinical grade.I in comparison with
patients classified as grade I (Figure 4D). The number
of CD31 cells in grade .I showed a tendency to a re-
duction that, however, did not reach the significance
level (Figure 4C).
In patients affected by either aGVHD or cGVHD,
skin biopsies from subjects refractory to the therapeu-
tic intervention showed a significantly lower number
of FOXP31 Tregs in comparison with the more ele-
vated number of FOXP31 Tregs found in skin speci-
mens from responsive subjects (Figure 4F). The
number of CD31 cells in responders appeared also
to be increased, but the difference was not statistically
different (Figure 4E). In the category of aGVHD
patients only, skin biopsies from patients refractory
to therapy had lower Tregs numbers in comparison
with skin biopsies from responsive patients (P5
.03). Finally, examining all transplanted patients
(with or without GVHD), the number of FOXP31
Tregs in biopsies taken before day 100 compared to bi-
opsies obtained after day 100 from transplantation
(Figure 4 G and H) did not show any significant
difference.DISCUSSION
A number of studies in murine models convinc-
ingly demonstrated that donor CD41/CD251 T cells
prevent GVHDwithout loss of donor T cell-mediated
graft versus leukemia effect [12-14]. However, inhumans, the role of these cells in preventing GVHD
after allo-HSCT has not been clearly defined. Foxp3
expression was significantly decreased in patients
with GVHD, the lowest values being found in the
most severe cases [15]. In addition, active cGVHD
correlates with decreased CD41/CD251Treg and re-
duced Foxp3 gene expression [19]. In addition, the
lower the number of FOXP31/CD41 T cells, the
greater the risk of developing GVHD [22]. However,
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Biol Blood Marrow Transplant 15:938-947, 2009 945Tregs in Skin GVHDother studies could not confirm the protective role of
Tregs in GVHD. A long-lasting reduction in
CD41 T cell reconstitution, affecting similarly
regulatory or nonregulatory cells, was shown follow-
ing allo-HSCT [20]. No significant difference be-
tween absolute numbers of CD41CD25high T cells
in patients with and without GVHDhas been reported[30]. Similarly, the ratio of PB FOXP31 per total leu-
kocytes or T cells was not found to predict the occur-
rence of GVHD [31]. Conversely, patients with
cGVHD were shown to have markedly elevated num-
bers of CD41CD25high T cells in the PB compared to
patients without GVHD [16]. Conflicting results most
likely reflect the difficulty to obtain a reliable
946 Biol Blood Marrow Transplant 15:938-947, 2009C. Fondi et al.identification of Tregs in PB, and the shortcomings as-
sociated to the use of CD4 and CD25 as selective
markers of Tregs phenotype. Robust evidence indi-
cates that Foxp3 immunostaining is a more suitable
tool to precisely identifying the Treg phenotype and
recent findings showed that it is possible to localize
Tregs in biopsies of GVHD target organs, as the intes-
tine [26].
A major finding of the present study is that the
number of FOXP31 Tregs in skin specimens from
aGVHD was higher than in cutaneous biopsies of
non-GVHD rashes, but lower than that of cutaneous
drug reactions. To our knowledge, only 1 study [26]
has directly investigated the Treg population at the
site ofGVHDreactivity.This study reported that in in-
testinal biopsies the number of CD81 T cells was sim-
ilarly elevated in patients with either GVHD or
intestinal CMV infection and diverticulitis compared
to the low T cell levels observed in specimens from
healthy controls (normal mucosa from patients
screened for colorectal cancer). In contrast, a negligible
level of FOXP31Tregs, similar to that seen in healthy
controls, was found in the intestinal mucosa of patients
with aGVHD compared to the elevated values ob-
served in CMV infection and diverticulitis [26]. In the
same study, specimens obtained from allografted pa-
tients with gastrointestinal (GI) symptoms, butwithout
the histologic signs of GVHD, showed a numbers of
FOXP31 Tregs, significantly higher than in GVHD
patients and similar to patients with CMV infection
of diverticulitis. CD81 were uniformly increased in
GVHD and CMV invention and diverticulitis com-
pared to healthy controls.
In our present study, CD31 T cell number was
similarly elevated in GVHD and skin drug reac-
tions, whereas a negligible amount of inflammatory
cells were recorded in skin specimens from allog-
rafted patients with erythema without subsequent
GVHD or from healthy skin. Interestingly, within
cutaneous CD41 T cells, 30% were FOXP31
among aGVHD patients and 50% were FOXP31
in both cGVHD and drug reactions. Thus, the pro-
portion of skin FOXP31 cells within CD41 cells
was remarkably increased in comparison to periph-
eral blood and this could be explained by FOXP3
induction after activation or preferential recruitment
of natural Tregs. In this context, it should be
underlined that previous studies have demonstrated
that the main changes in GVHD seem to affect
the CD81 T cell compartment.
Present findings confirm at the cutaneous level, as
previously found in the intestinal mucosa [26], that
both CD81 or CD31 cells, which drive the inflamma-
tory response, are markedly increased in target tissues
of GVHD as in other inflammatory conditions. How-
ever, whereas biopsies, from intestinal GVHD were
characterized by a low level of Tregs compared tothe elevated Tregs in non-GVHD rash specimens, in
skin biopsies, the number of Tregs in non-GVHD
rash specimens was negligible and similar to that found
in healthy skin. One possible explanation for the differ-
ent results between the present and previous article
[26] may be from a difference in the response to the al-
lograft procedure between the intestine and the skin.
In the intestine increases in resistance to depletion or
in migration to the tissue by Tregs may occur, whereas
these phenomena may be absent or less pronounced in
the skin.
A relevant result of the present investigation is the
finding that cutaneous GVHD patients with a better
response to therapy showed a higher number of
FOXP31 Tregs than patients with a poor response.
Although we found that the number of Tregs was
reduced in patients with higher clinical GVHDgrades,
we underline that, because of the relatively small sam-
ple size, our results should we interpreted with cau-
tion. However, present data obtained in cutaneous
GVHD are consistent with the previous hypothesis
[26] that an insufficient upregulation of FOXP31
Tregs in the target tissue contributes to the disease
severity and to the resistance to drug therapy.
The need for a valuable prognostic factor is of par-
ticular importance in the setting of allo-HSCT from
unrelated donors and the use of PBSC as graft source.
These conditions have modified the clinical pattern of
GVHD [32,33] and represent today a relevant subset
of the activity. Indeed new, more aggressive GVHD
prophylaxis strategies have further mixed up the clini-
cal onset of low-grade GVHD, resulting for the first-
line treatment in a challenging dilemma. Ideally, tim-
ing and intensity of the treatment should be adjusted
according to a reliable prognostic index. Skin biopsy
is an easy, minimally invasive diagnostic tool that is
now proposed also as a prognostic factor to be inte-
grated with more established parameters. Further in-
vestigation on a large cohort of patients is needed to
assess the role of skin biopsy within this context.ACKNOWLEDGMENTS
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